UCLA ’s Dennis Slamon awarded Sjöberg Prize for pioneering cancer research
Dr. Dennis Slamon, director of the Revlon/UCLA Women ’s Cancer Research Program, has been named a co-winner of the 2019 Sjöberg Prize by the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation. Honored for his groundbreaking research that led to the development of successful targeted cancer therapies, Slamon shares the award with D r. Brian Druker of Oregon Health& Science University.The Sj öberg Prize has been awarded annually since 2016 to recognize outstanding cancer research. The honor carries a prize of $1 million — $100,000 as award money and $900,000 to fund future ...
Source: UCLA Newsroom: Health Sciences - February 5, 2019 Category: Universities & Medical Training Source Type: news

Dr. John Mendelsohn, 82, Researcher Who Led Top Cancer Center, Dies
After pioneering a targeted cancer therapy, he oversaw MD Anderson in Houston as it gained a reputation as the nation ’ s top cancer hospital. (Source: NYT Health)
Source: NYT Health - January 18, 2019 Category: Consumer Health News Authors: KATIE THOMAS Tags: Mendelsohn, John Deaths (Obituaries) University of Texas M D Anderson Cancer Center Erbitux (Drug) ImClone Systems Inc Source Type: news

Cisplatin Superior to Cetuximab for HPV + Oropharyngeal Cancer
Toxicity similar in two treatment groups at 24 months, but worse tumor control with cetuximab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 17, 2018 Category: Cancer & Oncology Tags: Oncology, ENT, Pharmacy, Radiology, Journal, Source Type: news

Cisplatin Superior to Cetuximab for HPV+ Oropharyngeal Cancer
MONDAY, Dec. 17, 2018 -- For treatment of human papillomavirus (HPV)-positive low-risk oropharyngeal cancer, cetuximab shows no benefit compared with the standard cisplatin regimen in terms of reduced toxicity and results in worse tumor control,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 17, 2018 Category: Pharmaceuticals Source Type: news

Panitumumab cost saving versus  cetuximab
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news

Head & Neck Cancer: Mixed Results with Intensified Therapy
(MedPage Today) -- Concurrent chemo with cetuximab-RT improves PFS but not induction (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 7, 2018 Category: Primary Care Source Type: news

No De-escalation of Therapy for HPV+ Throat Cancer No De-escalation of Therapy for HPV+ Throat Cancer
De-escalating therapy by using cetuximab with radiotherapy did not improve side effects and, more importantly, had worse survival compared with chemoradiotherapy for patients with good prognosis HPV+ throat cancers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 26, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

RTOG 1016: Cisplatin Still Standard for HPV-Related Oral Cancer RTOG 1016: Cisplatin Still Standard for HPV-Related Oral Cancer
Cisplatin plus radiation therapy was superior to cetuximab/radiation therapy for all endpoints, but toxicity burden is much higherMedscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASTRO: Oropharynx CA Survival Rates Worse With RT/Cetuximab
FRIDAY, Oct. 26, 2018 -- For patients with locoregionally advanced human papillomavirus (HPV)-related oropharynx cancer, radiation/cetuximab results in inferior overall and progression-free survival versus radiation/cisplatin, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 26, 2018 Category: Pharmaceuticals Source Type: news

Cetuximab Fails Twice vs Cisplatin for HPV-Related Oral Ca
(MedPage Today) -- Cetuximab resulted in more patient deaths across U.S., German studies (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 23, 2018 Category: Hematology Source Type: news

Patients with HPV-positive oropharynx cancer should receive chemoradiation
(European Society for Medical Oncology) Patients with human papilloma virus (HPV)-positive throat cancer should receive chemoradiotherapy rather than cetuximab with radiotherapy, according to late-breaking research reported at the ESMO 2018 Congress in Munich. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news

No Change in Standard of Care for HPV+ Oropharyngeal Cancer No Change in Standard of Care for HPV+ Oropharyngeal Cancer
Interim results of a large phase III trial showed that patients treated with a cetuximab regimen has worse survival than those treated with cisplatin plus radiation therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cetuximab Failure in HPV+ Head and Neck Cancer
(MedPage Today) -- Inferior survival when paired with radiation therapy (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 16, 2018 Category: American Health Source Type: news

Chemicals in green vegetables show to prevent bowel cancer
Diets high in indole-3-carbinol protect stomach cells from chaotic division Related items fromOnMedica FOB associated with rise in all-cause mortality Colorectal cancer risk link to ‘inflammatory’ foods Taking aspirin with a PPI reduces risk of oesophageal cancer Cetuximab with chemo shrinks more secondaries Overweight teens more likely to have severe liver disease later (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 15, 2018 Category: UK Health Source Type: news

Study: Cetuximab, radiation inferior to standard HPV throat cancer treatment
Treating HPV-positive throat cancer with cetuximab and radiation had worse overall and progression-free survival compared with radiation and cisplatin. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 14, 2018 Category: Consumer Health News Source Type: news

Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancer
. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 14, 2018 Category: American Health Source Type: news

Cetuximab+RT found to be inferior to standard treatment in HPV+ oropharyngeal cancer
(NIH/National Cancer Institute) An interim analysis of data from a randomized clinical trial of patients with human papillomavirus (HPV)-positive oropharyngeal cancer found that treatment with radiation therapy and cetuximab is associated with worse overall and progression-free survival compared to the current standard treatment with radiation and cisplatin. The trial was designed to see if cetuximab with radiation would be less toxic than cisplatin with radiation without compromising survival for patients with the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 14, 2018 Category: Cancer & Oncology Source Type: news

Clinical trial suggests new direction for heavy-smoking head and neck cancer patients
(University of Colorado Anschutz Medical Campus) Phase I results of olaparib with cetuximab and radiation led to 72 percent 2-year survival in 16 patients on trial, compared with an expected 2-year survival rate of about 55 percent for standard-of-care treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 14, 2018 Category: International Medicine & Public Health Source Type: news

Can New Algorithm Shed Light on Treatment Resistance in Head and Neck Cancer?
The CoGAPS gene activity algorithm may elucidate molecular changes that occur as H&N tumors acquire resistance to cetuximab, says a Johns Hopkins team. (Source: CancerNetwork)
Source: CancerNetwork - July 30, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Pazopanib/Cetuximab Combo Promising in Recurrent, Metastatic Head and Neck Squamous Cell Carcinoma
A Washington University School of Medicine team ’s findings might inform future research into inhibitors of angiogenesis and PD-1 in head and neck cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 23, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

A Better Regimen for Head and Neck Cancer?
(MedPage Today) -- Study backs combo of chemotherapy, cetuximab, and radiotherapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 13, 2018 Category: Hematology Source Type: news

Second-Line Irinotecan/Cetuximab/Ramucirumab Combo Ups PFS in Advanced CRC
John SchieszerJun 6, 2018A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab –based therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Cetuximab and panitumumab cost  effective for mCRC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

A specific new ELISA method for analyzing cetuximab
This study describes the development and full validation of a new enzyme-linked immunosorbent assay (ELISA) with high sensitivity and selectivity for bioanalysis of CET. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2018 Category: Cancer & Oncology Source Type: news

Therapy Order Affects Survival in Metastatic CRC
(MedPage Today) -- Big gain with regorafenib before cetuximab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 21, 2018 Category: Primary Care Source Type: news

Cetuximab Paired With Dye Can Image Glioblastoma Cetuximab Paired With Dye Can Image Glioblastoma
The antibody cetuximab paired with a fluorescent dye can image glioblastoma during brain surgery, a pilot study showed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2017 Category: Consumer Health News Tags: General Surgery News Source Type: news

Vanderbilt researchers find novel mechanism of resistance to anti-cancer drugs
(Vanderbilt University Medical Center) Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported Oct. 16 in Nature Medicine, suggest a strategy for overcoming this resistance. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 16, 2017 Category: Cancer & Oncology Source Type: news

NICE recommends Merck ’s erbitux to treat R/M SCCHN in oral cavity
The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Merck ’s erbitux (cetuximab), in combination with platinum-based chemotherapy, to treat recurrent and / or metastatic (R/M) squamous cell carcinoma of t… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 9, 2017 Category: Pharmaceuticals Source Type: news

Results of NRG-RTOG 0436 highlight need for biomarkers in treatment of esophageal cancer
(NRG Oncology) NRG-RTOG 0436 has determined that adding an epidermal growth factor receptor (EGFR) inhibitor to a chemo-radiation regimen does not improve overall survival for patients with locally advanced esophageal cancer treated in a non-operative manner. These results are reported in 'Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients with Esophageal Cancer -- The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial,' which was recently published in the Journal of the American Medical Association Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 25, 2017 Category: International Medicine & Public Health Source Type: news

Erbitux (Cetuximab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 21, 2017 Category: Drugs & Pharmacology Source Type: news

Adding Cetuximab in Esophageal Cancer Fails to Improve Survival
Use of the EGFR inhibitor cetuximab with chemoradiation did not improve survival in patients with esophageal carcinoma compared with chemoradiation alone, according to the results of the phase III RTOG 0436 trial. (Source: CancerNetwork)
Source: CancerNetwork - July 13, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Esophageal Cancer Gastrointestinal Cancer News Source Type: news

SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in HNC
(InSilico Medicine, Inc.) The researchers identified that SMAD4 loss results in cetuximab resistance in vitro and poor survival in HPV-negative HNSCC patients and in vivo models. Using OncoFinder (an innovative bioinformatic tool currently rebranded as iPANDA), they revealed a signature of pro-survival and anti-apoptotic pathways specifically dysregulated in SMAD4-low HNSCCs and indicate JNK and MAPK activation as potential mediators of cetuximab resistance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 7, 2017 Category: International Medicine & Public Health Source Type: news

Oh, Lovely: The Tick That Gives People Meat Allergies Is Spreading
By Megan Molteni for WIRED. First comes the unscratchable itching, and the angry blossoming of hives. Then stomach cramping, and — for the unluckiest few — difficulty breathing, passing out, and even death. In the last decade and a half, thousands of previously protein-loving Americans have developed a dangerous allergy to meat. And they all have one thing in common: the lone star tick. Red meat, you might be surprised to know, isn’t totally sugar-free. It contains a few protein-linked saccharides, including one called galactose-alpha-1,3-galactose, or alpha-gal, for short. More and more people are lear...
Source: Healthy Living - The Huffington Post - June 20, 2017 Category: Consumer Health News Source Type: news

Adding vemurafenib doubles progression-free survival in BRAF metastatic colorectal cancer
(University of Colorado Anschutz Medical Campus) Clinical trial results presented in an oral abstract session 3:00pm Monday, June 5 at the American Society for Clinical Oncology (ASCO) Annual Meeting 2017 shows promising results for the addition of vemurafenib (anti-BRAF) to treatment with cetuximab and irinotecan (anti-EGFR) in patients with metastatic colorectal cancer that have a BRAF V600E mutation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 5, 2017 Category: Cancer & Oncology Source Type: news

NICE recommends Merck ’s Erbitux to treat patients with metastatic colorectal cancer
The UK National Institute for Health and Care Excellence (NICE) has issued a positive final appraisal determination (FAD) for Merck ’s Erbitux (cetuximab) to treat patients with RAS wild-type metastatic colorectal cancer (mCRC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 3, 2017 Category: Pharmaceuticals Source Type: news

Addition of Vemurafenib to Irinotecan/Cetuximab Delayed Progression in BRAF-Mutated mCRC
The addition of the BRAF inhibitor vemurafenib to irinotecan and cetuximab prolonged progression-free survival and resulted in a higher disease control rate than treatment with irinotecan and cetuximab alone in patients with BRAF-mutant metastatic colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Colorectal Cancer News Source Type: news

Vemurafenib Delayed Progression in Metastatic, BRAF-Mutant CRC
This video covers results of the SWOG 1406 study, which tested the BRAF inhibitor vemurafenib in combination with irinotecan and cetuximab for patients with metastatic, BRAF-mutant colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 23, 2017 Category: Cancer & Oncology Authors: Scott Kopetz, MD Tags: Conferences/ASCO 2017 Gastrointestinal Cancers Symposium Videos Gastrointestinal Cancers Source Type: news

Cetuximab Reduces Locoregional Failure in Anal Canal Carcinoma, Adds Toxicity
Adding cetuximab to chemoradiation yielded better locoregional failure rates than historical data in a small trial of patients with squamous cell carcinoma of the anal canal, but the treatment resulted in substantial toxicity. (Source: CancerNetwork)
Source: CancerNetwork - January 11, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gastrointestinal Cancer News Source Type: news

[Research Article] The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor
The kinase AXL promotes cetuximab resistance by promoting the nuclear accumulation of EGFR. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - January 3, 2017 Category: Science Authors: Toni M. Brand, Mari Iida, Kelsey L. Corrigan, Cara M. Braverman, John P. Coan, Bailey G. Flanigan, Andrew P. Stein, Ravi Salgia, Jana Rolff, Randall J. Kimple, Deric L. Wheeler Source Type: news

Roadmap to more personalized cancer treatment
People with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation, research has found. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 22, 2016 Category: Science Source Type: news

Study provides roadmap to more personalized cancer treatment
Milo Mitchell/UCLA Jonsson Comprehensive Cancer CenterUCLA ’s Dr. Joanne Weidhaas explains her latest research, which could lead to more personalized treatments for head and neck cancer. FINDINGSResearchers have found that people with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation.The study was led by UCLA Jonsson Comprehensive Cancer Center member Dr. Joanne Weidhaas in collaboration with colleagues at the NRG Oncology RTOG. ...
Source: UCLA Newsroom: Health Sciences - December 22, 2016 Category: Universities & Medical Training Source Type: news

Researchers find key to drug resistant bowel cancer
Blcoking a molecule could bypass bowel cancer ’s defense against the drug cetuximab, according to new research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 9, 2016 Category: Science Source Type: news

Researcher finds key to drug resistant bowel cancer
(Cancer Research UK) Blocking a molecule could bypass bowel cancer's defence against the drug cetuximab, according to new research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 8, 2016 Category: Cancer & Oncology Source Type: news

Cetuximab Continuation After First Progression in CRC Cetuximab Continuation After First Progression in CRC
Which molecular markers indicate that continuation of cetuximab in second-line therapy for colorectal cancer may be effective?Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Cetuximab Continuation After CRC Progression May Up PFS Cetuximab Continuation After CRC Progression May Up PFS
Dr David Kerr reports on a phase 2 study suggesting that continuation of cetuximab after progression may improve progression-free survival in patients with metastatic colorectal cancer. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 22, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Cetuximab Plus RT Not Ready for Prime Time in Laryngeal CancerCetuximab Plus RT Not Ready for Prime Time in Laryngeal Cancer
Outcomes favor cetuximab plus radiotherapy vs radiotherapy alone in laryngeal cancer, even though results are not statistically significant. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 7, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Combination chemo-radiation therapy may help preserve larynx for patients with laryngeal cancer
Researchers assessed the rates of laryngeal (having to do with the larynx [voice box]) preservation and laryngectomy-free survival in patients receiving the monoclonal antibody cetuximab and radiation therapy (CRT) or radiation therapy alone. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 7, 2016 Category: Science Source Type: news

Combination chemo-radiation therapy may help preserve larynx for patients with laryngeal cancer
(The JAMA Network Journals) In a study published online by JAMA Otolaryngology-Head & Neck Surgery, James A. Bonner, M.D., of the University of Alabama at Birmingham, and colleagues assessed the rates of laryngeal (having to do with the larynx [voice box]) preservation and laryngectomy-free survival in patients receiving the monoclonal antibody cetuximab and radiation therapy (CRT) or radiation therapy alone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2016 Category: Cancer & Oncology Source Type: news

Merck reports positive pivotal Phase III TAILOR study results of Erbitux and FOLFOX combination for mCRC
Merck has reported a positive outcome of pivotal Phase III TAILOR study of the combination of Erbitux (cetuximab) and FOLFOX to treat RAS wild-type, metastatic colorectal cancer (mCRC). (Source: Drug Development Technology)
Source: Drug Development Technology - July 3, 2016 Category: Pharmaceuticals Source Type: news

Cetuximab, panitumumab not cost effective for RAS WT CRC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 31, 2016 Category: Drugs & Pharmacology Source Type: news